Quanterix Co. (NASDAQ:QTRX) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 36.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,504 shares of the company’s stock after selling 5,965 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Quanterix were worth $287,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of QTRX. Vanguard Group Inc. raised its holdings in Quanterix by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,997,295 shares of the company’s stock valued at $54,207,000 after acquiring an additional 26,660 shares during the last quarter. Invesco Ltd. raised its holdings in Quanterix by 49.6% in the 3rd quarter. Invesco Ltd. now owns 1,103,981 shares of the company’s stock valued at $29,962,000 after acquiring an additional 366,117 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in Quanterix in the 3rd quarter valued at about $27,744,000. Boone Capital Management LLC raised its holdings in Quanterix by 13.4% in the 3rd quarter. Boone Capital Management LLC now owns 568,544 shares of the company’s stock valued at $15,430,000 after acquiring an additional 67,400 shares during the last quarter. Finally, Emerald Advisers LLC acquired a new stake in Quanterix in the 3rd quarter valued at about $10,462,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Scotiabank increased their price objective on shares of Quanterix from $30.00 to $32.00 and gave the company a “sector outperform” rating in a report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.00.

Insiders Place Their Bets

In other news, Director Laurie J. Olson sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the sale, the director now directly owns 15,238 shares of the company’s stock, valued at approximately $371,045.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.80% of the stock is currently owned by insiders.

Quanterix Stock Down 0.2 %

QTRX stock opened at $15.56 on Friday. Quanterix Co. has a 52-week low of $11.60 and a 52-week high of $29.70. The stock has a market cap of $595.17 million, a price-to-earnings ratio of -18.09 and a beta of 1.30. The business has a fifty day moving average of $22.74 and a two-hundred day moving average of $23.33.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). The business had revenue of $31.55 million for the quarter, compared to analysts’ expectations of $27.92 million. Quanterix had a negative return on equity of 9.15% and a negative net margin of 26.42%. As a group, sell-side analysts anticipate that Quanterix Co. will post -1.04 EPS for the current year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.